Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark C Markowski

Showing results (11-20 of 72) with videos related to

Pageof 8
Sort By:
Expert Opinion on Investigational Drugs|October 17, 2017
BET inhibitors in metastatic prostate cancer: therapeutic implications and rational drug combinationsMark C Markowski, Angelo M De Marzo, Emmanuel S Antonarakis
Nature Reviews. Urology|September 6, 2022
The shifting treatment paradigm of metastatic renal cell carcinomaYasser Ged, Mark C Markowski, Nirmish Singla, et al.
Expert Opinion on Investigational Drugs|March 1, 2023
Role of bromodomain and extraterminal (BET) proteins in prostate cancerAdel Mandl, Mark C Markowski, Michael A Carducci, et al.
Clinical Genitourinary Cancer|March 20, 2016
Lumbosacral Plexus Involvement as the First Site of Metastatic Recurrence in a Patient With CTNNB1-Mutant Prostate CancerMark C Markowski, Sara E Wobker, Roy E Strowd, et al.
Clinical Genitourinary Cancer|March 23, 2017
Long-Term Control of Oligometastatic Prostate Cancer After Stereotactic Body Radiotherapy in the Absence of Androgen Deprivation Therapy: A Case ReportMark C Markowski, Philip Imus, Jean L Wright, et al.
The Oncologist|April 7, 2023
Bipolar Androgen Therapy Followed by Androgen Receptor Inhibition as Sequential Therapy for Prostate CancerSamuel R Denmeade, Laura A Sena, Hao Wang, et al.
The Prostate|July 13, 2016
Cost-Savings Analysis of AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer Eligible for Treatment With Abiraterone or EnzalutamideMark C Markowski, Kevin D Frick, James R Eshleman, et al.
Urology|July 2, 2015
Sarcomatoid Carcinoma of the Prostate: Retrospective Review of a Case Series From the Johns Hopkins HospitalMark C Markowski, Mario A Eisenberger, Marianna Zahurak, et al.
European Journal of Cancer (Oxford, England : 1990)|January 11, 2023
Updated analyses for RESTORE cohort C: A trial of bipolar androgen therapy for patients with newly castration-resistant prostate cancerLaura A Sena, Tingchang Wang, Hao Wang, et al.
JCO Precision Oncology|November 25, 2017
Clinical Utility of CLIA-Grade AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate CancerMark C Markowski, John L Silberstein, James R Eshleman, et al.
Pageof 8

Showing results (11-20 of 72) with videos related to

Sort By:
Pageof 8
Expert Opinion on Investigational Drugs|October 17, 2017
BET inhibitors in metastatic prostate cancer: therapeutic implications and rational drug combinationsMark C Markowski, Angelo M De Marzo, Emmanuel S Antonarakis
Nature Reviews. Urology|September 6, 2022
The shifting treatment paradigm of metastatic renal cell carcinomaYasser Ged, Mark C Markowski, Nirmish Singla, et al.
Expert Opinion on Investigational Drugs|March 1, 2023
Role of bromodomain and extraterminal (BET) proteins in prostate cancerAdel Mandl, Mark C Markowski, Michael A Carducci, et al.
Clinical Genitourinary Cancer|March 20, 2016
Lumbosacral Plexus Involvement as the First Site of Metastatic Recurrence in a Patient With CTNNB1-Mutant Prostate CancerMark C Markowski, Sara E Wobker, Roy E Strowd, et al.
Clinical Genitourinary Cancer|March 23, 2017
Long-Term Control of Oligometastatic Prostate Cancer After Stereotactic Body Radiotherapy in the Absence of Androgen Deprivation Therapy: A Case ReportMark C Markowski, Philip Imus, Jean L Wright, et al.
The Oncologist|April 7, 2023
Bipolar Androgen Therapy Followed by Androgen Receptor Inhibition as Sequential Therapy for Prostate CancerSamuel R Denmeade, Laura A Sena, Hao Wang, et al.
The Prostate|July 13, 2016
Cost-Savings Analysis of AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer Eligible for Treatment With Abiraterone or EnzalutamideMark C Markowski, Kevin D Frick, James R Eshleman, et al.
Urology|July 2, 2015
Sarcomatoid Carcinoma of the Prostate: Retrospective Review of a Case Series From the Johns Hopkins HospitalMark C Markowski, Mario A Eisenberger, Marianna Zahurak, et al.
European Journal of Cancer (Oxford, England : 1990)|January 11, 2023
Updated analyses for RESTORE cohort C: A trial of bipolar androgen therapy for patients with newly castration-resistant prostate cancerLaura A Sena, Tingchang Wang, Hao Wang, et al.
JCO Precision Oncology|November 25, 2017
Clinical Utility of CLIA-Grade AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate CancerMark C Markowski, John L Silberstein, James R Eshleman, et al.
Pageof 8